{"organizations": [], "uuid": "a3f1db9a452ce75fc9a58ea3eefc6906687ebf2d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eleven-biotherapeutics-says-comple/brief-eleven-biotherapeutics-says-completed-enrollment-for-late-stage-bladder-cancer-study-idUSASC09RPR", "country": "US", "domain_rank": 408, "title": "BRIEF-Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T12:34:00.000+02:00", "replies_count": 0, "uuid": "a3f1db9a452ce75fc9a58ea3eefc6906687ebf2d"}, "author": "", "url": "https://www.reuters.com/article/brief-eleven-biotherapeutics-says-comple/brief-eleven-biotherapeutics-says-completed-enrollment-for-late-stage-bladder-cancer-study-idUSASC09RPR", "ord_in_thread": 0, "title": "BRIEF-Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study", "locations": [], "entities": {"persons": [], "locations": [{"name": "nmibc", "sentiment": "none"}], "organizations": [{"name": "eleven biotherapeutics inc", "sentiment": "none"}, {"name": "vista", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 12, 2018 / 10:35 AM / in 22 minutes BRIEF-Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study Reuters Staff March 12 (Reuters) - Eleven Biotherapeutics Inc: * ENROLLMENT COMPLETED IN PHASE 3 REGISTRATION TRIAL FOR NON-MUSCLE INVASIVE BLADDER CANCER * ELEVEN BIOTHERAPEUTICS INC - ‍VISTA TRIAL OF VICINIUM IN NMIBC ON-TRACK FOR TOPLINE THREE-MONTH DATA IN MID-2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-12T12:34:00.000+02:00", "crawled": "2018-03-12T13:02:15.028+02:00", "highlightTitle": ""}